These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22452894)

  • 1. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
    James ND; Sydes MR; Mason MD; Clarke NW; Anderson J; Dearnaley DP; Dwyer J; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann GN; Bertelli G; Birtle AJ; O'Sullivan JM; Protheroe A; Sheehan D; Srihari N; Parmar MK;
    Lancet Oncol; 2012 May; 13(5):549-58. PubMed ID: 22452894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
    Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
    Parker CC; James ND; Brawley CD; Clarke NW; Hoyle AP; Ali A; Ritchie AWS; Attard G; Chowdhury S; Cross W; Dearnaley DP; Gillessen S; Gilson C; Jones RJ; Langley RE; Malik ZI; Mason MD; Matheson D; Millman R; Russell JM; Thalmann GN; Amos CL; Alonzi R; Bahl A; Birtle A; Din O; Douis H; Eswar C; Gale J; Gannon MR; Jonnada S; Khaksar S; Lester JF; O'Sullivan JM; Parikh OA; Pedley ID; Pudney DM; Sheehan DJ; Srihari NN; Tran ATH; Parmar MKB; Sydes MR;
    Lancet; 2018 Dec; 392(10162):2353-2366. PubMed ID: 30355464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
    Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
    J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
    Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
    Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
    Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
    Parker CC; Clarke NW; Cook AD; Kynaston H; Catton CN; Cross WR; Petersen PM; Persad RA; Saad F; Bower LC; Logue J; Payne H; Forcat S; Goldstein C; Murphy C; Anderson J; Barkati M; Bottomley DM; Branagan J; Choudhury A; Chung PWM; Cogley L; Goh CL; Hoskin P; Khoo V; Malone SC; Masters L; Morris SL; Nabid A; Ong AD; Raman R; Tarver KL; Tree AC; Worlding J; Wylie JP; Zarkar AM; Parulekar WR; Parmar MKB; Sydes MR;
    Lancet; 2024 Jun; 403(10442):2405-2415. PubMed ID: 38763154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
    Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
    Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
    Sydes MR; Parmar MK; Mason MD; Clarke NW; Amos C; Anderson J; de Bono J; Dearnaley DP; Dwyer J; Green C; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann G; James ND
    Trials; 2012 Sep; 13():168. PubMed ID: 22978443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
    James ND; de Bono JS; Spears MR; Clarke NW; Mason MD; Dearnaley DP; Ritchie AWS; Amos CL; Gilson C; Jones RJ; Matheson D; Millman R; Attard G; Chowdhury S; Cross WR; Gillessen S; Parker CC; Russell JM; Berthold DR; Brawley C; Adab F; Aung S; Birtle AJ; Bowen J; Brock S; Chakraborti P; Ferguson C; Gale J; Gray E; Hingorani M; Hoskin PJ; Lester JF; Malik ZI; McKinna F; McPhail N; Money-Kyrle J; O'Sullivan J; Parikh O; Protheroe A; Robinson A; Srihari NN; Thomas C; Wagstaff J; Wylie J; Zarkar A; Parmar MKB; Sydes MR;
    N Engl J Med; 2017 Jul; 377(4):338-351. PubMed ID: 28578639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
    James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
    Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.